"The Onassis Foundation Science Lecture Series 2011 in Biology"

Basic and Applied Virology

July 15, 2011 Philip N. Tsichlis Molecular Oncology Research Institute Tufts Medical Center, Boston, MA

Oncogenes involved in the induction and progression of retrovirus-induced T cell lymphomas as probes of normal and neoplastic cell function.



Validation of the Insertional Mutagenesis Model of Oncogenesis

Avian Leukosis Virus-Induced Tumors Have Common Proviral Integration Sites and Synthesize Discrete New RNAs: Oncogenesis by Promoter Insertion

Benjamin G. Neel and William S. Hayward

The Rockefeller University New York, New York 10021 Harriet L. Robinson The Worcester Foundation for Experimental Biology Shrewsbury, Massachusetts 01545 Joanna Fang and Susan M. Astrin The Institute for Cancer Research The Fox Chase Cancer Center Philadelphia, Pennsylvania 19111

NATURE VOL. 302 31 MARCH 1983

A common region for proviral DNA integration in MoMuLV-induced rat thymic lymphomas

Philip N. Tsichlis, P. Gunter Strauss & Li Fu Hu

Laboratory of Tumor Virus Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, USA

Cell, Vol. 31, 99-109, November 1982, Copyright © 1982 by MIT

Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome

Roel Nusse* and Harold E. Varmus

Department of Microbiology and Immunology University of California San Francisco, California 94143 and * Department of Virology Antoni van Leeuwenhoekhuis Plesmanlaan 121 Amsterdam, The Netherlands

A Retroviral Oncogene, *akt*, Encoding a Serine-Threonine Kinase Containing an SH2-Like Region

Alfonso Bellacosa, Joseph R. Testa, Stephen P. Staal,* Philip N. Tsichlis†



Science, 254: 274, 1991.



Akt transforms cultured cells

Akt induces Lymphoid Tumors

Genetic structure of the Akt Kinase



AKT IS A TARGET OF THE PI-3 KINASE



Cell, 81: 727, 1995

Akt activation by growth factors



The PI-3K/Akt pathway in human cancer



Oncogene 27: 5497, 2008

Targeting the PI-3K/Akt pathway



Cell 129:1261, 2007

Inhibitors of the PI-3K/Akt pathway under development

Inhibitor	Company	Phase of clinical trial	Refs
Dual PI3K and mTOR inhibitors			
BEZ235	Novartis	Phase I/II	37,92,96,103,149
BGT226	Novartis	Phase I/II	NS
XL765	Exelixis	Phase I	NS
SF1126	Semafore	Phase I/II	NS
GSK1059615	GSK	Preclinical	150
PI3K inhibitors			
XL147	Exelixis	Phase I	NS
PX866	Oncothyreon	Phase I	100,151,152
GDC0941	Genentech/Piramed/Roche	Phase I	NS
BKM120	Novartis	Phase I	NS
CAL101 (targets p110δ)	Calistoga Pharmaceuticals	Phase I	NS
Akt inhibitors			
Perifosine	Keryx	Phase I/II	153–156
GSK690693	GSK	Phase I	157,158
VQD002	Vioquest	Phase I	NS
MK2206	Merck	Phase I	NS
mTOR inhibitors (catalytic site)			
OSI027	OSI Pharmaceuticals	Phase I	NS
AZD8055	AstraZeneca	Phase I/II	NS

NS, not stated.

Nature Reviews, Cancer 9: 550, 2009

There are three Akt isoforms, Akt1, Akt2 and Akt3

Akt1 is not Akt2 is not Akt3

For at least some of the Akt functions, the balance between isoforms is more important biologically, than the overall Akt activity

Akt1 ablation significantly delays, while Akt2 ablation accelerates the development of mammary adenocarcinomas in MMTV-Neu and MMTV-PyMT transgenic mice.





Mammary adenocarcinomas in Akt1 knockout mice are highly invasive



Combined ablation of Akt1 and Akt2 inhibits β -selection and the transition of DN thymocytes to the DP stage



Development of a new platform for the study of Akt isoform-specific properties





Quantitative profiling of post-translational modifications (phosphorylation)



Common-Individual Targets

Akt1 is not Akt2 Akt1 is not Akt3 Akt2 is not Akt3



Gene Ontology HeatMap of AKT Phosphoproteomics

Akt1 is not Akt2 Akt1 is not Akt3 Akt2 is not Akt3



p value

MicroRNA profiling of cells expressing indvidual Akt isoforms



MicroRNAs differentially regulated by Akt isoforms during IGF stimulation





MicroRNAs differentially regulated by Akt isoforms during Hypoxia





Pathways predicted to be differentially regulated by Akt isoforms during hypoxia, based on differences in microRNA gene expression



RNA/Pathway Cut off **3**

Targets of upregulated miRs





Targets of downregulated miRs





Targets of all dysregulated miRs





K[GG

Focus on Akt2

- MicroRNAs differentially regulated by Akt2 control EMT and stem cell renewal in cancer cells
- MicroRNAs differentially regulated by Akt2 render cells resistant to hypoxia
- Akt2, in the absence of Akt1 promotes inflammation

Akt isoforms have different microRNA gene signatures



Downregulation of the microRNAs of the miR-200 family in Akt2-expressing cells, may cause EMT and promote invasiveness



Model of EMT regulation by Akt1 and Akt2



EMT/Acquisition of Stem cell properties

Cells undergoing EMT via miR-200 downregulation, in response to TGFβ treatment and Akt1 knockdown, exhibit stem cell properties





Mammary adenocarcinomas developing in MMTV-cErbB2/Akt1^{-/-} mice express low levels of the miR-200 family members, high levels of Zeb1 and low levels of E-cadherin





The Akt/miR-200/E-cadherin axis contributes to the metastatic phenotype in the majority of human mammary adenocarcinomas.



An epigenetic network of neoplastic stem cells



Focus on Akt2

- MicroRNAs differentially regulated by Akt2 control EMT and stem cell renewal in cancer cells
- MicroRNAs differentially regulated by Akt2 render cells resistant to hypoxia
- Akt2, in the absence of Akt1 promotes inflammation

The hypoxia-activated Akt2-miR-21 PTEN axis



Both CREB binding and NF-κB binding to the miR-21 promoter are required for the activation of the promoter in Akt2-expressing cells exposed to hypoxia



CREB and NF-kB binding on the miR-21 promoter in cells exposed to hypoxia depend on Akt2 and not on Akt1



CBP binding and histone H3 acetylation at K9 in the miR-21 promoter in cells exposed to hypoxia depends primarily on Akt2



The hypoxia activated Akt2-miR-21-PTEN axis is functional in MMTV-PyMT-induced murine mammary adenocarcinomas and human ovarian carcinomas



Focus on Akt2

- MicroRNAs differentially regulated by Akt2 control EMT and stem cell renewal in cancer cells
- MicroRNAs differentially regulated by Akt2 render cells resistant to hypoxia
- Akt2 promotes, while Akt1 inhibits inflammation

The induction of pro-inflammatory mediators by LPS in Akt1-/- macrophages is normalized by the combination of let-7e and asmiR-155



Akt2 ablation downregulates the expression of proinflammatory mediators in macrophages in response to LPS



Akt1 and Akt2 isoforms differentially regulate macrophage polarization



Focus on Akt2

- MicroRNAs differentially regulated by Akt2 control EMT and stem cell renewal in cancer cells
- MicroRNAs differentially regulated by Akt2 render cells resistant to hypoxia
- Akt2, in the absence of Akt1, promotes inflammation
- Akt1 and Akt2 maintain self-tolerance by controlling the development of regulatory T cells.

Akt1/Akt2 double knockout mice develop hemolytic anemia



Akt1/Akt2 double knockout mice develop glomerulonephritis



Wild type

Lck-Cre/ Akt1^{fl/fl/}Akt2^{-/-}

Akt1/Akt2 double knockout mice develop widespread inflammation



Wild type mouse

Lck-Cre /Akt1^{fl/fl}/Akt2^{-/-}

The serum of Akt1/Akt2 double knockout mice contains antinuclear antibodies

C57BL/6



Lck-cre+*Akt1*^{fl/fl}2^{-/-} n=3



MRL/lpr

Lck-cre+*Akt1*^{fl/fl}2^{-/-}3^{-/-} n=2





Foxp3 + cells in the thymus of wt and Lck-Cre/Akt1fl/fl/Akt2-/- mice



CD4+/CD25+ cells in the spleen of Akt1/Akt2 double knockout mice express low levels of Foxp3



TCR and TGFβ stimulation of CD4+ T cells from Akt1/Akt2 double knockout mice induces Th17 cells rather than Tregs



Akt1/Akt2 DKO cell cultures and Akt1/Akt2 DKO animals produce high levels of IL-6.



Summary

- Identification of pathways activated or inhibited by sets of microRNAs, that are upregulated or downregulated by different Akt isoforms during IGF stimulation or hypoxia.
- Akt2 inhibits the expression of microRNAs of the miR-200 family. As a result, Akt2 promotes EMT, tumor cells invasiveness and the acquisition of stem cell properties by the tumor cells.
- Akt1 inhibits the effects of Akt2 on the expression of microRNAs that regulate EMT. As a result, it is the balance between Akt1 and Akt2, rather than the overall Akt activity, that regulates this process.
- Akt2 enhances resistance to hypoxia via microRNA-dependent mechanisms.
- Akt2 promotes inflammation. The differential effects of Akt1 and Akt2 on inflammation depend on differential microRNA regulation by the two isoforms
- Akt1 and Akt2 maintain self-tolerance by controlling the development of regulatory T cells.

Acknowledgements:

Christos Polytarchou Maria Hatziapostolou Ioanna Maroulakou Filippos Kottakis Zhu Shen Giannis Sanidas Changchuin Mao Scott Ezell

Kevin Struhl Dimitris Iliopoulos

Christos Tsatsanis Alicia Arranz Ariadne Androulidaki Vassiliki Zacharioudaki

Artemis Hatzigeorgiou George Papadopoulos